Mega%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv

# MegaCV ## Overview MegaCV is a combination product containing mesalamine and a controlled-release formulation of carbidopa-levodopa. The exact mechanism of MegaCV is not fully elucidated, but it is believed to involve the delivery of both mesalamine to the colon and carbidopa-levodopa systemically. ## Primary Indications MegaCV is indicated for the treatment of ulcerative colitis. ## Adult Dosing The typical adult dose is one tablet by mouth once daily. The dose may be titrated up to two tablets by mouth once daily. ## Pediatric Dosing No pediatric dosing has been established for MegaCV. ## Dose Adjustments * **Renal Impairment:** No specific dose adjustments are recommended. However, caution is advised as mesalamine is renally excreted. * **Hepatic Impairment:** No specific dose adjustments are recommended. However, caution is advised as mesalamine is metabolized in the liver. ## Contraindications * Known hypersensitivity to mesalamine, salicylates, carbidopa, levodopa, or any component of the formulation. * Certain severe cardiovascular diseases. * Certain psychiatric conditions. * Narrow-angle glaucoma. ## Adverse Effects * **Common:** Nausea, vomiting, abdominal pain, diarrhea, headache, dizziness, somnolence, constipation, and rash. * **Serious:** Renal impairment (including interstitial nephritis, nephrotic syndrome, renal failure), severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), blood dyscrasias, and pulmonary reactions. ## Key Drug Interactions * **Antihypertensives:** Concomitant use with levodopa may cause orthostatic hypotension. * **Anticholinergics:** May increase the absorption of levodopa. * **MAO Inhibitors:** Concurrent use with levodopa is contraindicated. * **Iron Supplements:** May decrease the absorption of levodopa. ## Monitoring * Renal function (BUN, creatinine) should be monitored regularly, especially in patients with pre-existing renal disease. * Liver function tests may be considered. * Monitor for signs and symptoms of hypersensitivity reactions and severe adverse effects. ## Clinical Pearls * Administer MegaCV with food to improve tolerability. * Do not crush, chew, or break the tablet; it must be swallowed whole. * Patients should be advised to report any new or worsening symptoms, including signs of kidney problems (e.g., changes in urine color or amount, swelling) or severe skin reactions. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*